Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / Malignant Colossus
Cytology Microscopy and imaging Professional Development

Malignant Colossus

A closer look at cellular scale in lung adenocarcinoma cytology

By Jessica Allerton 02/11/2026 Gallery 0 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Thought Leaders

Share

Clinical Scorecard: Malignant Colossus

At a Glance

CategoryDetail
ConditionLung Adenocarcinoma
Key MechanismsMalignant cell proliferation
Target PopulationPatients with lung adenocarcinoma
Care SettingCytopathology

Key Highlights

  • Photomicrograph of a large malignant cell
  • EBUS-guided FNA cytology used for diagnosis
  • Significance of cell size in malignancy assessment

Guideline-Based Recommendations

Diagnosis

  • Utilize EBUS-guided FNA for cytological evaluation

Management

  • Consider treatment options based on cytology results

Monitoring & Follow-up

  • Regular follow-up imaging and cytological assessments

Risks

  • Potential for misdiagnosis if cytological features are ambiguous

Patient & Prescribing Data

Individuals diagnosed with lung adenocarcinoma

Treatment plans should be tailored based on cytological findings

Clinical Best Practices

  • Ensure accurate sampling during EBUS-guided FNA
  • Evaluate cytological features comprehensively
  • Integrate cytology results with clinical findings for management decisions

References

  • Tania Labiano, Cytopathologist

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Intense Intestines
Microscopy and imaging
Intense Intestines

January 19, 2024

1 min read

Some powerful fluorescent microscopy in this Image of the Month…

Context Matters in Cancer Biology
Microscopy and imaging
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

When Pathology Goes 3D
Microscopy and imaging
When Pathology Goes 3D

February 2, 2022

1 min read

Stratifying cancers with non-destructive 3D pathology

Sacrificing Safety for Speed?
Microscopy and imaging
Sacrificing Safety for Speed?

February 4, 2022

3 min read

Wide adaptation of antigen testing could increase the risk of exposure to infectious SARS-CoV-2 samples

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.